Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib extended treatment safety study
NCT02921919Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in solid tumor, sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events up to 4.6 years, Grade 3 or 4 Treatment-Emergent Adverse Events up to 4.6 years and 5 more. Started Nov 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02921919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921919.